Literature DB >> 30283265

Clinical Lifestyle Medicine Strategies for Preventing and Reversing Memory Loss in Alzheimer's.

Paulina Shetty1,2, Wes Youngberg1,2.   

Abstract

Alzheimer's disease (AD) is the most common form of dementia and currently affects over 5 million Americans and 30 million individuals worldwide. Unfortunately, the current approach to treating AD provides nothing more than a marginal, unsustained, symptomatic effect, with little or no effect on disease progression itself. To attain effective improvements in AD, one must determine risk factors, address the underlying causes, and focus on a combination of functional and lifestyle medicine strategies that provide a comprehensive, programmatic, and network-based approach that is sufficient to achieve epigenetic transformation and neurologic healing through its multiple and necessary synergistic components. Rather than normalizing metabolic parameters, the focus is on optimization of each metabolic parameter. Papers published by research neurologist, Dr Dale Bredesen have documented that symptoms of mild cognitive impairment and early AD may often be reversed within 6 months after initiating a comprehensive, functional and lifestyle medicine-focused program. The purpose of this article are as follows: 1. Shed light on a promising clinical protocol that focuses on a comprehensive functional and lifestyle medicine approach to treating mild cognitive decline and Alzheimer's disease; 2. Identify the Bredesen Protocol testing, diagnostic and treatment guidelines; 3. Review several case studies and discuss the promising results of the program. Although published case studies such as those reported here are relatively few, clinicians applying these comprehensive strategies have reason to expect improvement in their patients. Lifestyle medicine can be a source of greatly needed hope for those suffering with cognitive decline.

Entities:  

Keywords:  Alzheimer’s disease; cognitive impairment; dementia; lifestyle medicine

Year:  2018        PMID: 30283265      PMCID: PMC6146367          DOI: 10.1177/1559827618766468

Source DB:  PubMed          Journal:  Am J Lifestyle Med        ISSN: 1559-8276


  5 in total

1.  2014 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2014-03       Impact factor: 21.566

2.  Contribution of Alzheimer disease to mortality in the United States.

Authors:  Bryan D James; Sue E Leurgans; Liesi E Hebert; Paul A Scherr; Kristine Yaffe; David A Bennett
Journal:  Neurology       Date:  2014-03-05       Impact factor: 9.910

3.  Reversal of cognitive decline: a novel therapeutic program.

Authors:  Dale E Bredesen
Journal:  Aging (Albany NY)       Date:  2014-09       Impact factor: 5.682

4.  Metabolic profiling distinguishes three subtypes of Alzheimer's disease.

Authors:  Dale E Bredesen
Journal:  Aging (Albany NY)       Date:  2015-08       Impact factor: 5.682

5.  Reversal of cognitive decline in Alzheimer's disease.

Authors:  Dale E Bredesen; Edwin C Amos; Jonathan Canick; Mary Ackerley; Cyrus Raji; Milan Fiala; Jamila Ahdidan
Journal:  Aging (Albany NY)       Date:  2016-06       Impact factor: 5.682

  5 in total
  2 in total

1.  Disease-directed engineering for physiology-driven treatment interventions in neurological disorders.

Authors:  Thomas Wood; Elizabeth Nance
Journal:  APL Bioeng       Date:  2019-10-23

Review 2.  Personalized Management and Treatment of Alzheimer's Disease.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Olaia Martínez-Iglesias; Lola Corzo; Natalia Cacabelos; Rocío Pego; Juan C Carril
Journal:  Life (Basel)       Date:  2022-03-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.